Cox univariable and multivariable model for TTNT from second-line therapy and OS from first relapse
| Variable . | Univariable . | Multivariable-adjusted . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| TTNT fromsecond-linetherapy | ||||||
| Age older than 65 y | 0.90 | 0.80-1.01 | .08 | 1.05 | 0.90-1.22 | .54 |
| Sex, male vs female | 1.11 | 0.98-1.25 | .09 | 1.13 | 0.98-1.32 | .87 |
| At diagnosis: | ||||||
| ISS stage III vs I/II | 1.39 | 1.23-1.58 | <.001 | 1.35 | 1.16-1.57 | <.001 |
| High-risk FISH | 1.97 | 1.68-2.30 | <.001 | 1.80 | 1.52-2.14 | <.001 |
| EMD | 1.04 | 0.87-1.24 | .68 | — | — | — |
| Non-secretory disease | 1.20 | 0.88-1.63 | .26 | — | — | — |
| Novel agents in first-line treatment | 0.90 | 0.77-1.05 | .40 | — | — | — |
| Best response for first-line treatment ≥VGPR vs <VGPR | 0.94 | 0.81-1.09 | .85 | — | — | — |
| First-line ASCT | 0.82 | 0.73-0.92 | <.001 | 0.84 | 0.72-0.98 | .03 |
| Lenalidomide-based maintenance after first-line therapy | 1.06 | 0.89-1.27 | .48 | — | — | — |
| CP vs BP | 1.44 | 1.28-1.62 | <.001 | 1.40 | 1.20-1.62 | <.001 |
| Relapse during primary or maintenance treatment | 1.38 | 1.22-1.55 | <.001 | 1.26 | 1.08-1.47 | .004 |
| OS from first relapse | ||||||
| Age older than 65 y | 1.40 | 1.23-1.59 | <.001 | 1.47 | 1.24-1.75 | <.001 |
| Sex, male vs female | 1.21 | 1.06-1.38 | .006 | 1.23 | 1.04-1.47 | .02 |
| At diagnosis: | ||||||
| ISS stage, III vs I/II | 1.54 | 1.34-1.77 | <.001 | 1.58 | 1.33-1.88 | <.001 |
| High risk FISH | 2.14 | 1.81-2.53 | <.001 | 1.94 | 1.61-2.34 | <.001 |
| EMD | 1.43 | 1.19-1.73 | <.001 | 1.37 | 1.07-1.74 | .01 |
| Non-secretory disease | 1.07 | 0.76-1.52 | .69 | — | — | — |
| Novel agents in first-line treatment | 0.86 | 0.73-1.01 | .06 | — | — | — |
| Best response for first-line treatment ≥VGPR vs <VGPR | 0.97 | 0.85-1.11 | .65 | — | — | — |
| First-line ASCT | 0.72 | 0.63-0.82 | <.001 | 0.95 | 0.79-1.14 | .58 |
| Lenalidomide-based maintenance after first-line therapy | 0.89 | 0.72-1.09 | .25 | — | — | — |
| CP vs BP | 1.67 | 1.47-1.91 | <.001 | 1.53 | 1.29-1.81 | <.001 |
| Relapse during primary or maintenance treatment | 1.56 | 1.36-1.78 | <.001 | 1.31 | 1.10-1.57 | .003 |
| Variable . | Univariable . | Multivariable-adjusted . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| TTNT fromsecond-linetherapy | ||||||
| Age older than 65 y | 0.90 | 0.80-1.01 | .08 | 1.05 | 0.90-1.22 | .54 |
| Sex, male vs female | 1.11 | 0.98-1.25 | .09 | 1.13 | 0.98-1.32 | .87 |
| At diagnosis: | ||||||
| ISS stage III vs I/II | 1.39 | 1.23-1.58 | <.001 | 1.35 | 1.16-1.57 | <.001 |
| High-risk FISH | 1.97 | 1.68-2.30 | <.001 | 1.80 | 1.52-2.14 | <.001 |
| EMD | 1.04 | 0.87-1.24 | .68 | — | — | — |
| Non-secretory disease | 1.20 | 0.88-1.63 | .26 | — | — | — |
| Novel agents in first-line treatment | 0.90 | 0.77-1.05 | .40 | — | — | — |
| Best response for first-line treatment ≥VGPR vs <VGPR | 0.94 | 0.81-1.09 | .85 | — | — | — |
| First-line ASCT | 0.82 | 0.73-0.92 | <.001 | 0.84 | 0.72-0.98 | .03 |
| Lenalidomide-based maintenance after first-line therapy | 1.06 | 0.89-1.27 | .48 | — | — | — |
| CP vs BP | 1.44 | 1.28-1.62 | <.001 | 1.40 | 1.20-1.62 | <.001 |
| Relapse during primary or maintenance treatment | 1.38 | 1.22-1.55 | <.001 | 1.26 | 1.08-1.47 | .004 |
| OS from first relapse | ||||||
| Age older than 65 y | 1.40 | 1.23-1.59 | <.001 | 1.47 | 1.24-1.75 | <.001 |
| Sex, male vs female | 1.21 | 1.06-1.38 | .006 | 1.23 | 1.04-1.47 | .02 |
| At diagnosis: | ||||||
| ISS stage, III vs I/II | 1.54 | 1.34-1.77 | <.001 | 1.58 | 1.33-1.88 | <.001 |
| High risk FISH | 2.14 | 1.81-2.53 | <.001 | 1.94 | 1.61-2.34 | <.001 |
| EMD | 1.43 | 1.19-1.73 | <.001 | 1.37 | 1.07-1.74 | .01 |
| Non-secretory disease | 1.07 | 0.76-1.52 | .69 | — | — | — |
| Novel agents in first-line treatment | 0.86 | 0.73-1.01 | .06 | — | — | — |
| Best response for first-line treatment ≥VGPR vs <VGPR | 0.97 | 0.85-1.11 | .65 | — | — | — |
| First-line ASCT | 0.72 | 0.63-0.82 | <.001 | 0.95 | 0.79-1.14 | .58 |
| Lenalidomide-based maintenance after first-line therapy | 0.89 | 0.72-1.09 | .25 | — | — | — |
| CP vs BP | 1.67 | 1.47-1.91 | <.001 | 1.53 | 1.29-1.81 | <.001 |
| Relapse during primary or maintenance treatment | 1.56 | 1.36-1.78 | <.001 | 1.31 | 1.10-1.57 | .003 |
HR, hazard ratio.